Nrx Pharmaceuticals Stock Today
| NRXP Stock | USD 1.31 0.05 3.97% |
Performance0 of 100
| Odds Of DistressOver 81
|
NRX Pharmaceuticals is selling at 1.31 as of the 26th of November 2024; that is 3.97 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.26. NRX Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for NRX Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of September 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of December 2017 | Category Healthcare | Classification Health Care |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. The company has 12.09 M outstanding shares of which 682.66 K shares are now shorted by private and institutional investors with about 4.8 trading days to cover. More on NRX Pharmaceuticals
Moving together with NRX Stock
Moving against NRX Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NRX Stock Highlights
| CEO Secretary | Stephen Esq | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsNRX Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NRX Pharmaceuticals' financial leverage. It provides some insight into what part of NRX Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
NRX Pharmaceuticals (NRXP) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 13 people. NRX Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.24 M. NRX Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.09 M outstanding shares of which 682.66 K shares are now shorted by private and institutional investors with about 4.8 trading days to cover.
NRX Pharmaceuticals currently holds about 24.55 M in cash with (21.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Check NRX Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of NRX Pharmaceuticals is $15.24 Million. NRX Pharmaceuticals holds large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check NRX Ownership Details
NRX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-06-30 | 3.3 K | |
| Wells Fargo & Co | 2024-06-30 | 1.5 K | |
| Ubs Group Ag | 2024-06-30 | 1.1 K | |
| Goss Wealth Management Llc | 2024-06-30 | 583 | |
| Qube Research & Technologies | 2024-06-30 | 117 | |
| Harbour Investments, Inc. | 2024-09-30 | 47.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 34.0 | |
| Larson Financial Group, Llc | 2024-06-30 | 22.0 | |
| Vanguard Group Inc | 2024-09-30 | 240.3 K | |
| Anson Funds Management Lp | 2024-09-30 | 142.5 K | |
| Advisorshares Investments, Llc | 2024-09-30 | 130.1 K |
NRX Pharmaceuticals Historical Income Statement
NRX Stock Against Markets
NRX Pharmaceuticals Corporate Management
| Suzanne Messere | Investor Relations | Profile | |
| Robert MIM | Chief Operations | Profile | |
| Michael Kunz | Gen Sec | Profile | |
| Molly Cogan | Sr Affairs | Profile | |
| Seth Voorhees | CFO Treasurer | Profile |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.